63 results
8-K
EX-99.1
LIANY
LianBio
30 Oct 23
LianBio Announces Topline Results from Phase 3 LIBRA Trial of
4:16pm
with a safety profile similar to that observed in other large-scale clinical trials, and there were no treatment-related discontinuations.
LianBio plans … that the LIBRA trial demonstrated significant Demodex mite eradication, the primary etiology of Demodex blepharitis, as well as a favorable safety profile
8-K
EX-99.1
LIANY
LianBio
14 Aug 23
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
demonstrated a safety profile consistent with previous studies.
In April 2023, the China NMPA accepted with priority review the NDA for mavacamten
8-K
EX-99.1
7hlkc zd4
11 May 23
LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-99.1
6zyfl r5uq
1 May 23
Regulation FD Disclosure
7:28am
8-K
EX-99.1
e5dqi
26 Apr 23
LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients
8:07am
8-K
4n9 99qly
26 Apr 23
LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients
8:07am
8-K
EX-99.1
58ro73ci95o
21 Apr 23
Other Events
4:13pm
8-K
EX-99.1
5vx6z1f5oy2
19 Dec 22
Entry into a Material Definitive Agreement
7:04am
S-3/A
563d6afkv 3rp
9 Dec 22
Shelf registration (amended)
4:32pm
S-3
EX-25.1
dv1ukz8vo v9scuai88n
10 Nov 22
Shelf registration
5:26pm
S-3
8as kekgw9elx3
10 Nov 22
Shelf registration
5:26pm
8-K
EX-99.2
uzv1ick0tjf
10 Nov 22
LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.2
waybl207oy9zk
11 Aug 22
LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:30pm